Harvard Bioscience (HBIO) Enterprise Value (2010 - 2026)

Harvard Bioscience (HBIO) has reported Enterprise Value for 17 consecutive years, with $21.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 76.88% year-over-year to $21.5 million in Q2 2026; TTM through Jun 2026 was $21.5 million, a 76.88% increase from a year earlier, with the FY2025 full-year figure at $21.3 million, down 75.98% from the prior year.
• Enterprise Value was $21.5 million for Q2 2026 at Harvard Bioscience, up from $14.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at $250.7 million in Q1 2022 and troughed at $12.2 million in Q2 2025.
• A 5-year average of $112.4 million and a median of $112.4 million in 2022 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 103.36% in 2023 and slumped 89.89% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $112.1 million in 2022, then surged by 103.36% to $227.9 million in 2023, then plunged by 60.99% to $88.9 million in 2024, then plunged by 75.98% to $21.3 million in 2025, then grew by 0.68% to $21.5 million in 2026.
• The last three Enterprise Value figures came in at $21.5 million (Q2 2026), $14.9 million (Q1 2026), and $21.3 million (Q4 2025), per Business Quant data.